Efficacy of etanercept for the treatment of XXXX according to the onset type.

@entity1 @entity625 @entity548 @entity146 @entity1333 @entity1596 @entity30 @entity4932 @entity281 @entity1781 @entity1017 @entity3043
OBJECTIVE: To assess the efficacy of etanercept in @entity1 with @entity4932 ( @entity4932 ), and to assess the tolerance of these @entity1 to etanercept. METHODS: All @entity4932 @entity1 with active chronic @entity625 , who were first treated with etanercept between November 1999 and June 2001 in 18 French centers because of poor response or intolerance to methotrexate, were included in this open-label, prospective, multicenter study. A standardized questionnaire was sent to the treating physicians. We assessed the validated international core-set score for @entity4932 activity every 3 months and performed an intent-to-treat analysis. We also compared the risk of treatment failure in @entity1 defined as having systemic-onset, @entity4932 . RESULTS: Sixty-one @entity1 were enrolled and were followed up for a median of 13 months. Treatment had to be stopped in 1 @entity1 who became pregnant and in 12 @entity1 due to severe side effects, including neurologic or @entity146 , @entity1781 , major @entity1017 , severe @entity281 , @entity1333 with systemic symptoms, @entity548 , @entity1596 flare, and @entity3043 . All of these side effects disappeared after discontinuation of etanercept. @entity30 was subsequently diagnosed in 1 @entity1 . Scores improved by > or =30% in 73% of @entity1 after 3 months, but this proportion decreased to 39% after 12 months. The response rate was significantly lower in @entity1 with systemic-onset @entity4932 than in those with oligoarticular- or polyarticular-onset @entity4932 . CONCLUSION: Treatment of @entity4932 with etanercept may be associated with a wide spectrum of severe side effects. Although most @entity1 initially respond to etanercept, this initial response is not always followed by sustained improvement over longer periods of time. In addition, the higher rate of treatment failure in the group with systemic-onset @entity4932 indicates that these @entity1 in particular may require alternative treatments.
